Abattis Bioceuticals Corp. (OTCPK:ATTB.F) announces a share repurchase program. Under the normal course issuer bid, the company will repurchase up to 20,986,909 of its common shares, representing 5% of its issued and outstanding share capital. The shares repurchased will be cancelled. The bid will expire on August 15, 2019, or on an earlier date in the event that the number of common shares sought in the bid has been repurchased or if the company feels that it is appropriate to do so.